Loading…

Sandoz committed approximately $400 million to construct a new biologics plant in Lendava, Slovenia, for manufacturing biosimilars. Construction is expected to start later in 2023, with the site becoming fully operational in 2026, adding around 300 jobs.
“This investment underscores our ambition to be the sustainable global leader in biosimilars, a segment projected to grow double-digit annually over the next decade.”endpoints.news
Summarized from public sources; check the original articles before acting on it.